SOURCE: Equity Markets Inc.

July 07, 2011 09:00 ET

Research Report on Pain Therapeutics, Inc. and Cephalon, Inc. -- Companies Help You Feel Better

MACAU--(Marketwire - Jul 7, 2011) - Today, www.EquityMarketsInc.com announced its research report highlighting Pain Therapeutics, Inc. and Cephalon, Inc. Full content and research is available at www.EquityMarketsInc.com/research.php.

This sector demonstrates renewed investor interest as new and lucrative therapies come to market. It is expected that a wider acceptance of biomarker research and genetic-targeted clinical studies to help limit expense. It is viewed that therapeutics for cancer and infectious diseases and autoimmune and inflammatory treatments are primary growth areas. The FDA approved the first new drug in 50 years to treat auto-immune disorder lupus in March 2011, and we expect approval of new treatments for Hepatitis C virus around mid-year. The 2010 health care reform act authorized by the FDA, will establish a regulatory pathway for approving "biosimilar" drugs, which in turn will increase production and shorten FDA approval times.

Equity Markets has reviewed Pain Therapeutics, Inc. as a biopharmaceutical company that develops drugs. The Company has four drug candidates in clinical programs, including REMOXY, abuse-resistant hydromorphone, abuse-resistant hydrocodone and a radio-labeled monoclonal antibody to treat metastatic melanoma. It is also working on a new treatment for patients with hemophilia. It has a collaboration agreement with King Pharmaceuticals, Inc. (King) which develops and commercializes REMOXY and other opioid painkillers. The full research report on Pain Therapeutics, Inc. is available here: www.EquityMarketsInc.com/researchfile4634.php.

Equity Markets is covering Cephalon, Inc. as a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. The Company is engaged in providing medicines to patients in several therapeutic areas, with a particular focus on central nervous system (CNS) disorders, pain, oncology, inflammatory disease and regenerative medicine. The Company markets numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries. The full research report on Cephalon, Inc. is available here: www.EquityMarketsInc.com/researchfile4891.php.

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information